Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma

Autor: Nakul Dar, Sarah E. Gradecki, Elizabeth M. Gaughan

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

Targeted therapies, including BRAF and MEK inhibitors, are valuable treatment options for patients with unresectable or metastatic BRAF V600-mutant melanoma. With the improvement in survival seen with modern melanoma therapeutics, clinicians are lear

Externí odkaz: https://doaj.org/article/a0bef9328c294209ad55a72c70d14246

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI

Autor: Joe-Elie Salem, Enriqueta Felip, Shuchi Anand, Karolina Benesova, Marlies Ostermann, Ala Abudayyeh, Omar Mamlouk, Umut Selamet, Grace Cherry, Sunandana Chandra, Sandra M Herrmann, Maria Jose Soler, Abhijat Kitchlu, Jamie S Lin, Kerry L Reynolds, Elizabeth M Gaughan, Eva Muñoz-Couselo, Jamie S Hirsch, Pablo Garcia, Meghan E Sise, Thibaud Koessler, Mark Eijgelsheim, Shruti Gupta, Frank B Cortazar, Jason M Prosek, Ilya Glezerman, Shveta S Motwani, Naoka Murakami, Rimda Wanchoo, David I Ortiz-Melo, Arash Rashidi, Ben Sprangers, Vikram Aggarwal, A Bilal Malik, Sebastian Loew, Christopher A Carlos, Pazit Beckerman, Zain Mithani, Chintan V Shah, Amanda D Renaghan, Sophie De Seigneux, Luca Campedel, Daniel Sanghoon Shin, Sunil Rangarajan, Priya Deshpande, Gaia Coppock, Marium Husain, Clara Garcia-Carro, Sheila Bermejo, Nuttha Lumlertgul, Nina Seylanova, Busra Isik, Aydin Kaghazchi, Yuriy Khanin, Sheru K Kansal, Kai M Schmidt-Ott, Raymond K Hsu, Maria C Tio, Harkarandeep Singh, Kenar D Jhaveri, David E Leaf, Corinne Isnard Bagnis, Suraj S Mothi, Weiting Chang, Vipulbhai Sakhiya, Daniel Stalbow, Sylvia Wu, Armando Cennamo, Anne Rigg, Nisha Shaunak, Zoe A Kibbelaar, Harish S Seethapathy, Meghan Lee, Ian A Strohbhen, Ilya G Glezerman, Dwight H Owen, Sharon Mini, Andrey Kisel, Nicole Albert, Katherine Carter, Vicki Donley, Tricia Young, Heather Cigoi, Els Wauters Ben Sprangers, Javier A Pagan, Jonathan J Hogan, Valda Page, Samuel AP Short, Maria Josep Carreras, Sethu M. Madhavan

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)

Background Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adve

Externí odkaz: https://doaj.org/article/a6f6e1b57fb14e89bf208b6a482d2a1a

Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series

Autor: Puja Arora, Laura Talamo, Patrick Dillon, Ryan D. Gentzler, Trish Millard, Michael Salerno, Craig L. Slingluff, Elizabeth M. Gaughan

Publikováno v: Cardio-Oncology, Vol 6, Iss 1, Pp 1-11 (2020)

Abstract Background Immune checkpoint inhibition is part of standard systemic management for many advanced malignancies. Toxicities from this treatment approach are unpredictable, though usually reversible with management per established guidelines.

Externí odkaz: https://doaj.org/article/d2c780cf67664090a1984d81ad26ed4f

Acute kidney injury in patients treated with immune checkpoint inhibitors

Autor: Joe-Elie Salem, Enriqueta Felip, Sophie Papa, Shuchi Anand, Karolina Benesova, Marlies Ostermann, Ala Abudayyeh, Omar Mamlouk, Umut Selamet, Grace Cherry, Sunandana Chandra, Sandra M Herrmann, Maria Jose Soler, Abhijat Kitchlu, Jamie S Lin, Kerry L Reynolds, Osama E Rahma, Elizabeth M Gaughan, Eva Muñoz-Couselo, Jamie S Hirsch, Pablo Garcia, Meghan D Lee, Harish Seethapathy, Ian A Strohbehn, Meghan E Sise, Wei-Ting Chang, Els Wauters, Lucy Flanders, Deborah Schrag, Thibaud Koessler, Mark Eijgelsheim, Shruti Gupta, Frank B Cortazar, Samuel A P Short, Jason M Prosek, Sethu M Madhavan, Ilya Glezerman, Shveta S Motwani, Naoka Murakami, Rimda Wanchoo, David I Ortiz-Melo, Arash Rashidi, Ben Sprangers, Vikram Aggarwal, A Bilal Malik, Sebastian Loew, Christopher A Carlos, Pazit Beckerman, Zain Mithani, Chintan V Shah, Amanda D Renaghan, Sophie De Seigneux, Luca Campedel, Daniel Sanghoon Shin, Sunil Rangarajan, Priya Deshpande, Gaia Coppock, Dwight H. Owen, Marium Husain, Clara Garcia-Carro, Sheila Bermejo, Nuttha Lumlertgul, Nina Seylanova, Busra Isik, Aydin Kaghazchi, Yuriy Khanin, Sheru K Kansal, Kai M Schmidt-Ott, Raymond K Hsu, Maria C Tio, Suraj Sarvode Mothi, Harkarandeep Singh, Kenar D Jhaveri, David E Leaf, Corinne Isnard Bagnis, Suraj S Mothi, Weiting Chang, Vipulbhai Sakhiya, Daniel Stalbow, Sylvia Wu, Armando Cennamo, Anne Rigg, Nisha Shaunak, Zoe A Kibbelaar, Harish S Seethapathy, Meghan Lee, Ian A Strohbhen, Ilya G Glezerman, Dwight H Owen, Sharon Mini, Andrey Kisel, Nicole Albert, Katherine Carter, Vicki Donley, Tricia Young, Heather Cigoi, Els Wauters Ben Sprangers, Javier A Pagan, Jonathan J Hogan, Valda Page, Samuel AP Short, Maria Josep Carreras

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer.Methods We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis conte

Externí odkaz: https://doaj.org/article/f9d13db10fbd4d48a6d213cfb0b136b5

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

Autor: Kelly T Smith, Nikole Varhegyi, Nolan A Wages, Emily H Hall, Kathleen Haden, Craig L Slingluff, Jr., Lynn T Dengel, Anna Dickinson, Caroline Reed, Elizabeth M Gaughan, Varinder Kaur, Nadejda V Galeassi

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)

Background Peptide vaccines designed to stimulate melanoma-reactive CD4+ T cells can induce T cell and antibody (Ab) responses, associated with enhanced overall survival. We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incompl

Externí odkaz: https://doaj.org/article/0f1633d6e6534feb8dfa73c25184c8d5